» Articles » PMID: 37949903

IL-4 and IL-13 Induce Equivalent Expression of Traditional M2 Markers and Modulation of Reactive Oxygen Species in Human Macrophages

Overview
Journal Sci Rep
Specialty Science
Date 2023 Nov 10
PMID 37949903
Authors
Affiliations
Soon will be listed here.
Abstract

In cardiovascular disease, pathological and protective roles are reported for the Th2 cytokines IL-4 and IL-13, respectively. We hypothesised that differential effects on macrophage function are responsible. Type I and II receptor subunit (IL-2Rγ, IL-4Rα and IL-13Rα1) and M2 marker (MRC-1, CCL18, CCL22) expression was assessed via RT-qPCR in IL-4- and IL-13-treated human primary macrophages. Downstream signalling was evaluated via STAT1, STAT3 and STAT6 inhibitors, and IL-4- and IL-13-induced reactive oxygen species (ROS) generation assessed. IL-4 and IL-13 exhibited equivalent potency and efficacy for M2 marker induction, which was attenuated by STAT3 inhibition. Both cytokines enhanced PDBu-stimulated superoxide generation however this effect was 17% greater with IL-4 treatment. Type I IL-4 receptor expression was increased on M1-like macrophages but did not lead to a differing ability of these cytokines to modulate M1-like macrophage superoxide production. Overall, this study did not identify major differences in the ability of IL-4 and IL-13 to modulate macrophage function, suggesting that the opposing roles of these cytokines in cardiovascular disease are likely to be via actions on other cell types. Future studies should directly compare IL-4 and IL-13 in vivo to more thoroughly investigate the therapeutic validity of selective targeting of these cytokines.

Citing Articles

Bacterial-Mediated In Situ Engineering of Tumour-Associated Macrophages for Cancer Immunotherapy.

Kuhl G, Tangney M Cancers (Basel). 2025; 17(5).

PMID: 40075571 PMC: 11899205. DOI: 10.3390/cancers17050723.


ZIP8 Regulates Inflammation and Macrophage Polarisation in Intervertebral Disc Degeneration via the Wnt/β-Catenin Pathway.

Xu J, Gu H, Zhou K, Wu L, Zhang Y, Bian C J Cell Mol Med. 2025; 29(4):e70431.

PMID: 39993958 PMC: 11850097. DOI: 10.1111/jcmm.70431.


NADPH Oxidases in Cancer Therapy-Induced Cardiotoxicity: Mechanisms and Therapeutic Approaches.

Adhab A, Altalbawy F, Mahdi M, Baldaniya L, Omar T, Ganesan S Cardiovasc Toxicol. 2025; 25(4):631-649.

PMID: 39966326 DOI: 10.1007/s12012-025-09976-4.


Exploring Advances in Natural Plant Molecules for Allergic Rhinitis Immunomodulation in Vivo and in Vitro.

Li B, Dong B, Xie L, Li Y Int J Gen Med. 2025; 18:529-565.

PMID: 39911299 PMC: 11796455. DOI: 10.2147/IJGM.S493021.


The emerging role of alternatively activated macrophages to treat acute liver injury.

Humphries C, Addison M, Dear J, Forbes S Arch Toxicol. 2024; 99(1):103-114.

PMID: 39503878 PMC: 11742291. DOI: 10.1007/s00204-024-03892-2.


References
1.
Sorescu D, Weiss D, Lassegue B, Clempus R, Szocs K, Sorescu G . Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation. 2002; 105(12):1429-35. DOI: 10.1161/01.cir.0000012917.74432.66. View

2.
Boccardi V, Paolacci L, Croce M, Baroni M, Ercolani S, Cecchetti R . Lower serum levels of IL-13 is associated with increased carotid intima-media thickness in old age subjects. Aging Clin Exp Res. 2019; 32(7):1289-1294. DOI: 10.1007/s40520-019-01313-4. View

3.
Junttila I, Mizukami K, Dickensheets H, Meier-Schellersheim M, Yamane H, Donnelly R . Tuning sensitivity to IL-4 and IL-13: differential expression of IL-4Ralpha, IL-13Ralpha1, and gammac regulates relative cytokine sensitivity. J Exp Med. 2008; 205(11):2595-608. PMC: 2571934. DOI: 10.1084/jem.20080452. View

4.
Stein M, Keshav S, Harris N, Gordon S . Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med. 1992; 176(1):287-92. PMC: 2119288. DOI: 10.1084/jem.176.1.287. View

5.
Lee Y, Kim P, Lee W, Hirani A . Interleukin-4, Oxidative Stress, Vascular Inflammation and Atherosclerosis. Biomol Ther (Seoul). 2010; 18(2):135-144. PMC: 2975581. DOI: 10.4062/biomolther.2010.18.2.135. View